↓ Skip to main content

Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee

Overview of attention for article published in Clinical Drug Investigation, August 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#30 of 1,035)
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

policy
5 policy sources
patent
6 patents

Citations

dimensions_citation
197 Dimensions

Readers on

mendeley
132 Mendeley
Title
Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee
Published in
Clinical Drug Investigation, August 2012
DOI 10.2165/11533440-000000000-00000
Pubmed ID
Authors

Marc Afilalo, Mila S. Etropolski, Brigitte Kuperwasser, Kathy Kelly, Akiko Okamoto, Ilse Van Hove, Achim Steup, Bernd Lange, Christine Rauschkolb, Juergen Haeussler

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Norway 1 <1%
Argentina 1 <1%
Unknown 129 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 29 22%
Student > Master 16 12%
Other 14 11%
Student > Bachelor 10 8%
Student > Ph. D. Student 10 8%
Other 22 17%
Unknown 31 23%
Readers by discipline Count As %
Medicine and Dentistry 50 38%
Pharmacology, Toxicology and Pharmaceutical Science 13 10%
Nursing and Health Professions 6 5%
Agricultural and Biological Sciences 5 4%
Neuroscience 4 3%
Other 20 15%
Unknown 34 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 October 2020.
All research outputs
#1,550,483
of 25,374,917 outputs
Outputs from Clinical Drug Investigation
#30
of 1,035 outputs
Outputs of similar age
#9,427
of 187,955 outputs
Outputs of similar age from Clinical Drug Investigation
#7
of 344 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,035 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 187,955 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 344 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.